| Previous Close | 3.18 |
| Open | 3.18 |
| Bid | 0.00 x |
| Ask | 0.00 x |
| Day's Range | 3.01 - 3.18 |
| 52 Week Range | 0.84 - 3.88 |
| Volume | 30,470 |
| Avg. Volume | 37,878 |
| Market Cap | 240.28M |
| Beta | 0.91 |
| PE Ratio (TTM) | -5.10 |
| EPS (TTM) | -0.6 |
| Earnings Date | N/A |
| Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.00 |
Capital Cube•19 days agoSIGA Technologies, Inc. :SIGA-US: Earnings Analysis: Q1, 2017 By the Numbers : June 9, 2017
Categories: Yahoo FinanceGet free summary analysis SIGA Technologies, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of SIGA Technologies, Inc. – Achillion Pharmaceuticals, Inc., Emergent BioSolutions Inc., SciClone Pharmaceuticals, Inc., Novavax, Inc., Sarepta Therapeutics, Inc., Chimerix, Inc., BioCryst Pharmaceuticals, Inc. and Newlink Genetics Corporation (ACHN-US, ... Read more (Read more...)
- GlobeNewswire•27 days ago
SIGA to Present at the Jefferies Global Healthcare Conference on June 9, 2017
NEW YORK, May 31, 2017-- SIGA Technologies, Inc., a company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats, today announced that Dr. Phillip ...
- GlobeNewswire•2 months ago
SIGA Completes Enrollment and Dosing in Final Cohort of Phase I Study of IV Formulation of TPOXX® (tecovirimat) to Treat Smallpox
NEW YORK, April 20, 2017-- SIGA Technologies, Inc., a company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats, today announced the completion ...